Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1210031
                    [Title] => Bristol-Myers skin cancer drug Yervoy misses goal in study of additional, prostate cancer use
                    [Summary] => 
Bristol-Myers Squibb Co.'s skin cancer treatment Yervoy missed a main goal of achieving a significant improvement in overall survival compared to a fake drug when tested in patients with an advanced form of prostate cancer, the drugmaker said Thursday.

                    [DatePublished] => 2013-09-14 06:11:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img842.imageshack.us/img842/7071/3hew.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 706062
                    [Title] => European regulators OK Bristol-Myers cancer drug
                    [Summary] => 
Drugmaker Bristol-Myers Squibb Co. said Thursday the European Commission has approved its treatment Yervoy for use in adults with previously treated advanced melanoma, the deadliest type of skin cancer.
                    [DatePublished] => 2011-07-15 01:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

        )

)

YERVOY

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1210031
                    [Title] => Bristol-Myers skin cancer drug Yervoy misses goal in study of additional, prostate cancer use
                    [Summary] => 
Bristol-Myers Squibb Co.'s skin cancer treatment Yervoy missed a main goal of achieving a significant improvement in overall survival compared to a fake drug when tested in patients with an advanced form of prostate cancer, the drugmaker said Thursday.

                    [DatePublished] => 2013-09-14 06:11:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img842.imageshack.us/img842/7071/3hew.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 706062
                    [Title] => European regulators OK Bristol-Myers cancer drug
                    [Summary] => 
Drugmaker Bristol-Myers Squibb Co. said Thursday the European Commission has approved its treatment Yervoy for use in adults with previously treated advanced melanoma, the deadliest type of skin cancer.
                    [DatePublished] => 2011-07-15 01:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

        )

)

abtest

Bristol-Myers skin cancer drug Yervoy misses goal in study of additional, prostate cancer use

September 14, 2013 - 6:11am

Bristol-Myers Squibb Co.'s skin cancer treatment Yervoy missed a main goal of achieving a significant improvement in overall...

Health And Family

European regulators OK Bristol-Myers cancer drug

July 15, 2011 - 1:00am

Drugmaker Bristol-Myers Squibb Co. said Thursday the European Commission has approved its treatment Yervoy for use in adults with previously treated advanced melanoma, the deadliest type of skin cancer.